Figure 4.

Association factors for a targeted therapy—related adverse event or therapy adjustment (dose reduction, treatment disruption). Multivariable logistic regression (n = 222) adjusting for age, the UICC tumor stage and add-on Helixor^® VA treatment, as well as surgery, chemotherapy (CTX), radiation and the respective type of targeted therapy. Red dots indicate the odds ratio (OR). CDKi, CDK 4/6-inhibitors; ICI, immune checkpoint inhibitors; mAB, monoclonal antibody; PARPi, PARP-inhibitor; TKI, TKI-inhibitors; AE, adverse event; Brier Score, 0.046, Nagelkerke_R2, 0.2145.